- Home
- SDIG vs EPIX Comparison
SDIG vs EPIX Comparison
Compare SDIG & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDIG
- EPIX
- Stock Information
- Founded
- SDIG 2021
- EPIX 2009
- Country
- SDIG United States
- EPIX Canada
- Employees
- SDIG N/A
- EPIX N/A
- Industry
- SDIG Investment Bankers/Brokers/Service
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- SDIG Finance
- EPIX Health Care
- Exchange
- SDIG Nasdaq
- EPIX Nasdaq
- Market Cap
- SDIG 84.3M
- EPIX 73.5M
- IPO Year
- SDIG 2021
- EPIX N/A
- Fundamental
- Price
- SDIG $4.10
- EPIX $1.60
- Analyst Decision
- SDIG Buy
- EPIX Hold
- Analyst Count
- SDIG 3
- EPIX 3
- Target Price
- SDIG $7.25
- EPIX $2.00
- AVG Volume (30 Days)
- SDIG 586.3K
- EPIX 319.7K
- Earning Date
- SDIG 11-13-2024
- EPIX 12-17-2024
- Dividend Yield
- SDIG N/A
- EPIX N/A
- EPS Growth
- SDIG N/A
- EPIX N/A
- EPS
- SDIG N/A
- EPIX N/A
- Revenue
- SDIG $76,388,781.00
- EPIX N/A
- Revenue This Year
- SDIG $7.96
- EPIX N/A
- Revenue Next Year
- SDIG $27.28
- EPIX N/A
- P/E Ratio
- SDIG N/A
- EPIX N/A
- Revenue Growth
- SDIG N/A
- EPIX N/A
- 52 Week Low
- SDIG $1.65
- EPIX $1.40
- 52 Week High
- SDIG $11.56
- EPIX $11.67
- Technical
- Relative Strength Index (RSI)
- SDIG 38.26
- EPIX 23.81
- Support Level
- SDIG $4.84
- EPIX $1.57
- Resistance Level
- SDIG $5.24
- EPIX $1.74
- Average True Range (ATR)
- SDIG 0.43
- EPIX 0.06
- MACD
- SDIG -0.11
- EPIX 0.09
- Stochastic Oscillator
- SDIG 8.85
- EPIX 14.29
About SDIG Stronghold Digital Mining Inc.
Stronghold Digital Mining Inc is a vertically integrated crypto asset mining company currently focused on mining Bitcoin. The company has two reporting segments; Energy Operations and Cryptocurrency Operations. It generates maximum revenue from the Cryptocurrency Operations segment.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.